Mass General Brigham
Health Plan

Zelapar (selegiline) ODT
Effective 04/17/2019

Plan	☐ MassHealth UPPL ☒Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical and Specialty Medications** All Plans | Phone: 877-519-1908 | Fax: 855-540-3693		
	Non-Specialty Medications All Plans | Phone: 800-711-4555 | Fax: 844-403-1029		
Exceptions	N/A		

Overview
Zelapar is FDA indicated as adjunct therapy in the management of patients with Parkinson disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy

Coverage Guidelines
Authorization may be granted when the following criteria are met, and documentation has been submitted:

1. Member has been started and stabilized on Zelapar within the past 180 days (Note: Physician samples are not considered adequate justification for started & stabilized) **AND**
2. Member is currently taking carbidopa/levodopa

OR

1. Member is unable to swallow pills or use a conventional dosage form **AND**
2. Member is not currently receiving other oral solid dosage forms

Limitations

1. Approvals are granted for 12 months.

References

1. Zelapar (selegiline) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; August 2016

Review History
04/23/07 – Reviewed
09/21/09 – Updated
09/27/10 – Reviewed
12/15/10 – Updated disclaimer
09/19/11 – Reviewed
09/24/12 – Reviewed
09/23/13 – Reviewed

09/22/14 – Reviewed
09/21/15 – Reviewed
09/19/16 – Reviewed
09/18/17 – Reviewed
04/17/19 – Reviewed
11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.